First-in-human study of ABBV-637, an EGFR-targeting BCL-XL-inhibiting antibody-drug conjugate combined with osimertinib (OSI) in relapsed/refractory, EGFR-mutated non-small cell lung cancer (NSCLC)

被引：3
|
作者：
Rotow, J. K. [1 ]
Waqar, S. N. [2 ]
Papadopoulos, K. P. [3 ]
Hung, J-Y. [4 ,5 ]
Spira, A. I. [6 ]
Gan, H. [7 ]
Yoshida, T. [8 ]
Kuo, C-H. S. [9 ]
Doger de Speville, B. [10 ]
Felip, E. [11 ]
Yoh, K. [12 ]
Morrison-Thiele, G. [13 ]
Robinson, R. [14 ]
Rudraganguly, N. [14 ]
Saab, R. [15 ]
Cho, B. C. [16 ]
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, Lowe Ctr Thorac Oncol, Boston, MA USA
[2] Washington Univ, Med, Sch Med St Louis, Siteman Canc Ctr, St Louis, MO USA
[3] South Texas Accelerated Res Therapeut START, Dept Clin Res, San Antonio, TX USA
[4] Kaohsiung Med Univ, Div Pulm & Crit Care Med, Dept Internal Med, Kaohsiung, Taiwan
[5] Kaohsiung Med Univ, Kaohsiung Municipal Ta Tung Hosp, Coll Med, Fac Med, Kaohsiung, Taiwan
[6] Virginia Canc Specialists, Dept Med Oncol, US Oncol Res, Fairfax, VA USA
[7] Austin Hlth Austin Hosp, Dept Med Oncol, Heidelberg, Vic, Australia
[8] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan
[9] Chang Gung Univ, Chang Gung Mem Hosp, Div Thorac Oncol & Intervent Bronchoscopy, Dept Resp Med, Taipei, Taiwan
[10] START Madrid Hosp Univ, Fdn Jimenez Diaz, Madrid, Spain
[11] Vall dHebron Univ Hosp, Med Oncol Serv, Lung Canc Unit, Barcelona, Spain
[12] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan
[13] AbbVie Inc, Oncol Early Discovery, Headquarters, N Chicago, IL USA
[14] AbbVie Inc, San Francisco, CA USA
[15] AbbVie Inc, Clin Res, San Francisco, CA USA
[16] Yonsei Univ, Med Oncol Dept 501, ABMRC, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2352
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1318MO
引用
收藏
页数：1
相关论文
共 48 条
  • [31] Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC)
    Cappuzzo, F.
    Moreno Garcia, V.
    Ou, S-H. I.
    Brandao, M.
    Sanmamed, M. F.
    Helissey, C.
    Wislez, M.
    Call, J. A.
    Grisanti, S.
    Johnson, M. L.
    Boni, V.
    Jamme, P.
    Monnet, I.
    Siena, S.
    Yan, C.
    Barasa, B.
    Richard, B.
    Joe, A. K.
    Laus, G.
    Felip, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S1671 - S1671
  • [32] Telisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFR-mutated, c-met overexpressing, non-small cell lung cancer (NSCLC): Safety and efficacy results from phase Ib study
    Horinouchi, H.
    Goldman, J. W.
    Cho, B. C.
    Tomasini, P.
    Dunbar, M.
    Hoffman, D.
    Parikh, A.
    Blot, V.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2022, 33 : S1592 - S1592
  • [33] First-in-human phase 1 study of the antibody-drug conjugate (ADC) SAR408701 in advanced solid tumors: Dose-expansion cohort of patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC).
    Gazzah, Anas
    Cousin, Sophie
    Boni, Valentina
    Ricordel, Charles
    Kim, Tae Min
    Kim, Jin-Soo
    Helissey, Carole
    Gardeazabal, Itziar
    Chadjaa, Mustapha
    Allard, Aurore
    Yoruk, Semra
    Barlesi, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] An open-label, first-in-human study of BAY2927088 in patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation
    Tan, Daniel
    Goto, Koichi
    Loong, Herbert Hf
    Yang, Tsung-Ying
    Gadgeel, Shirish
    Massarelli, Erminia
    Daniele, Gennaro
    Le, Xiuning
    Shinno, Yuki
    Murakami, Haruyasu
    Sakamoto, Tomohiro
    Ruffinelli, Jose C.
    Lu, Shun
    Zhang, Yiping
    Kim, Tae Min
    Brennan, Barbara J.
    Chen, Chunlin
    Joosten, Miranda
    Wang, Zebin
    Pu, Su-Fen
    Bao, Weichao
    Kornacker, Martin
    Ferraldeschi, Roberta
    Grassi, Paolo
    Goh, Boon Cher
    CANCER RESEARCH, 2023, 83 (08)
  • [35] Propensity score matching analysis for osimertinib versus comparator first-generation EGFR tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: A Chinese, multicenter, real-world cohort study
    Zhang, D.
    Liu, X.
    Shen, F.
    Zhao, D.
    Shi, Y.
    Zhang, H.
    Liu, J.
    Gao, X.
    Chen, M.
    Zhao, J.
    Zhong, W.
    Xu, Y.
    Wang, M.
    ANNALS OF ONCOLOGY, 2023, 34
  • [36] Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.
    Lim, Sun Min
    Tan, Jiunn-Liang
    Dias, Josiane Mourao
    Voon, Pei Jye
    How, Soon Hin
    Zhou, Xiangdong
    Xiong, Hailin
    Massuti, Bartomeu
    Medley, Louise C.
    Nagasaka, Misako
    Vicente, David
    Girard, Nicolas
    Rittmeyer, Achim
    Botesteanu, Dana-Adriana
    Alhadab, Ali
    Mahoney, Janine M.
    Zhang, Jie
    Bauml, Joshua Michael
    Baig, Mahadi
    Scott, Susan Combs
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA8612 - LBA8612
  • [37] First-in-human study of AC0010, a novel irreversible, mutant-selective EGFR inhibitor in patients with 1st generation EGFR TKI-resistant non-small cell lung cancer (NSCLC)
    Zhang, L.
    Zhao, H.
    Hu, B.
    Jiang, J.
    Zheng, X.
    Zhang, Y.
    Ma, Y.
    Ge, J.
    Zou, B.
    Fang, X.
    Xu, W.
    Xu, X.
    ANNALS OF ONCOLOGY, 2016, 27
  • [38] Phase Ib study of telisotuzumab vedotin (Teliso-V) and osimertinib in patients (Pts) with advanced EGFR-mutated (Mut), c-Met overexpressing (OE) non-small cell lung cancer (NSCLC): Final efficacy and safety updates
    Horinouchi, H.
    Cho, B. C.
    Camidge, D. R.
    Goto, K.
    Tomasini, P.
    Li, Y.
    Vasilopoulos, A.
    Brunsdon, P.
    Hoffman, D.
    Shi, W.
    Blot, V.
    Goldman, J. W.
    ANNALS OF ONCOLOGY, 2023, 34 : S1670 - S1670
  • [39] BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with non-small cell lung cancer: Updated results from first-in-human phase I study
    Zhang, L.
    Ma, Y.
    Zhao, Y.
    Fang, W. F.
    Zhao, H.
    Huang, Y.
    Yang, Y.
    Hou, X.
    Wen, Z.
    Zhang, S.
    Wang, J.
    Xiao, S.
    Wang, H.
    Zhu, H.
    Olivo, M. S.
    Zhu, Y.
    ANNALS OF ONCOLOGY, 2023, 34
  • [40] Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study
    Zhang, Dongming
    Liu, Xiaoyan
    Shen, Fangfang
    Zhao, Dahai
    Shi, Yuequan
    Zhang, Haoran
    Liu, Jia
    Gao, Xiaoxing
    Chen, Minjiang
    Zhao, Jing
    Zhong, Wei
    Gao, Junzhen
    He, Min
    Liu, Yonggang
    Yang, Xiaoling
    Qin, Jianwen
    Tang, Yuling
    Mu, Xinlin
    Gu, Yangchun
    Zhang, Shucai
    Chen, Xueqin
    Pang, Li
    Meng, Qingwei
    Guo, Ye
    Zhang, Yuhui
    Li, Wei
    Xing, Puyuan
    Cheng, Yuan
    Xin, Tao
    Li, Qingxia
    Li, Yu
    Chen, Jun
    Gao, Feng
    Jin, Bo
    Rossi, Antonio
    Adachi, Hiroyuki
    Guerrera, Francesco
    Husain, Hatim
    Xu, Yan
    Wang, Mengzhao
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (11) : 2229 - +
12345